Contrasting Corcept Therapeutics (NASDAQ:CORT) and ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Volatility & Risk

ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.

Institutional and Insider Ownership

76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ANI Pharmaceuticals and Corcept Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Corcept Therapeutics	6.52%	8.26%	6.45%

Analyst Recommendations

This is a summary of recent recommendations for ANI Pharmaceuticals and Corcept Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	4	4	0	2.50
Corcept Therapeutics	1	2	5	0	2.50

ANI Pharmaceuticals currently has a consensus target price of $103.00, suggesting a potential upside of 36.62%. Corcept Therapeutics has a consensus target price of $138.17, suggesting a potential upside of 20.29%. Given ANI Pharmaceuticals’ higher probable upside, equities research analysts clearly believe ANI Pharmaceuticals is more favorable than Corcept Therapeutics.

Earnings and Valuation

This table compares ANI Pharmaceuticals and Corcept Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37 million	1.96	$78.34 million	$4.64	16.25
Corcept Therapeutics	$761.41 million	16.31	$99.65 million	$0.42	273.48

Corcept Therapeutics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.